Cardinal Health, Inc. (CAH) is scheduled to report  fiscal first-quarter 2025 results on Nov. 1, before the opening bell.In the last reported quarter, the company delivered an earnings surprise of 6.98%. CAH’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 13.47%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q1 Estimates for Cardinal HealthFor the fiscal first quarter, the consensus mark for earnings is pegged at ...

Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.87%. The prescription drug distributor's shares have seen a decrease of 0.58% over the last month, surpassing the Medical sector's loss of 3% and falling behind the S&P 500's gain of 4.87%. Investors ...

Cardinal Health (CAH) and T2 Biosystems recently entered into a multi-year exclusive U.S. agreement, selecting CAH as an exclusive distributor to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel.Likely Trend of CAH Stock Following the NewsFollowing the announcement, shares of the company traded at $111.32 at yesterday’s closing.Cardinal Health's pharmaceutical and med ...

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® ...

Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers Accelerates the development of Navista oncology practice alliance, adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states DUBLIN, Ohio, Sept. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a definitive agreement ...

The latest trading session saw Cardinal Health (CAH) ending at $110.76, denoting a -0.58% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 1.7%. Elsewhere, the Dow gained 1.26%, while the tech-heavy Nasdaq added 2.51%.Shares of the prescription drug distributor have appreciated by 1.61% over the course of the past month, outperforming the Medical sector's gain of 1.53% and the S&P 500's gain of 1.27%.Market participants will be closely following the finan ...

Cardinal Health (CAH) and Australia-based Telix recently entered a deal, selecting CAH as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's PET agent, Zircaix, for the imaging of kidney cancer in the United States, subject to regulatory approval.Telix and Cardinal Health already have a contract in place under which CAH has successfully commercialized Telix’s PSMA-PET imaging, Illuccix, approved for diagnosing prostate cancer in men.Likely Trend of CAH Stock Following the ...

Cardinal Health (CAH) closed the latest trading day at $113.28, indicating a +0.1% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.13% for the day. Elsewhere, the Dow saw an upswing of 0.55%, while the tech-heavy Nasdaq depreciated by 0.52%. The prescription drug distributor's shares have seen an increase of 3.02% over the last month, not keeping up with the Medical sector's gain of 3.34% and the S&P 500's gain of 3.67%. The investment community will ...

- Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients - The gene therapy was well tolerated with no treatment-related serious adverse events (SAEs) reported - Despite novel scientific advancements achieved with this program, the data do not warrant additional capital investment at this time and the gene therapy budget is being significantly reduced PALO ALTO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Br ...

Cardinal Health, Inc. (NYSE:CAH) Baird's 2024 Global Healthcare Conference September 10, 2024 9:05 AM ET Company Participants Matt Sims - VP, IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Eric Coldwell - Baird Eric Coldwell Good morning, everyone. My name is Eric Coldwell. I cover pharma services, healthcare and distribution, a broad list of related healthcare business service type entities, and it's a great pleasure to have Cardinal Health with us here today. Before we get going, I'm g ...